RAF signaling in neuroendocrine neoplasms: from bench to bedside

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neuroendocrine neoplasms (NENs) are heterogeneous, low-incidence malignancies with limited targeted therapy options due to a lack of predictive biomarkers.
• The mitogen-activated protein kinase (MAPK) pathway, including the RAF family, is implicated in various cancers, with BRAF inhibitors effective in some, like melanoma.

Purpose of the Study:

• To review the scientific and clinical data regarding RAF signaling in advanced neuroendocrine neoplasms.
• To explore the potential therapeutic roles of RAF activators and inhibitors in NENs.

Main Methods:

• Review of preclinical and clinical studies on RAF signaling in cancer.
• Analysis of mutation data and therapeutic responses in neuroendocrine neoplasms.
• Literature search focusing on RAF pathway components and their clinical relevance.

Main Results:

• BRAF mutations are rare in neuroendocrine neoplasms.
• RAF-1 activation, unlike BRAF mutations, has shown preclinical evidence of inhibiting tumor growth in NENs.
• Few targeted agents for NENs have progressed to late-stage clinical trials.

Conclusions:

• RAF-1 activators represent a promising therapeutic strategy for advanced neuroendocrine neoplasms, distinct from BRAF inhibitors.
• Further clinical investigation of RAF-1 activators is warranted for NEN treatment.
• Understanding RAF signaling is crucial for developing effective targeted therapies for NENs.